WO2004022096A1 - Method of treatment of asthma using antibodies to complement component c5 - Google Patents
Method of treatment of asthma using antibodies to complement component c5 Download PDFInfo
- Publication number
- WO2004022096A1 WO2004022096A1 PCT/US2003/027808 US0327808W WO2004022096A1 WO 2004022096 A1 WO2004022096 A1 WO 2004022096A1 US 0327808 W US0327808 W US 0327808W WO 2004022096 A1 WO2004022096 A1 WO 2004022096A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administering
- antibody
- subject
- compounds
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
Definitions
- TECHNICAL FIELD This disclosure relates to a method of treating asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components such as, for example, a complement-inhibiting antibody.
- bronchitis and emphysema are known collectively as Chronic Obstructive Pulmonary Diseases. These diseases are characterized as generalized airways obstruction, especially of small airways, associated with varying degrees of symptoms of chronic bronchitis, asthma, and emphysema. These diseases may often coexist in an individual, and it may be difficult to determine the primary cause of an airway obstruction. Airway obstruction is defined as an increased resistance to airflow during forced expiration.
- Obstruction of large airways may also occur in these diseases, particularly in asthma.
- Asthma is a reversible obstructive pulmonary disorder caused by an airway hyper-responsiveness to specific and/ or non-specific stimuli. Asthmatic airway obstruction typically results from bronchospasms. Asthma may be triggered by a variety of causes such as allergic reactions, a secondary response to infections, industrial or occupational exposures, ingestion of certain chemicals or drugs, exercise, and vasculitis. Much of asthma's pathology can be attributed to mast cell degranulation. Mast cells will degranulate in response to various conditions such as, for example, classical IgE-antigen stimulation. It is believed that when the asthmatic, human or animal, inhales an allergenic substance, sensitized IgE antibodies trigger mast cell degranulation in the lung interstitium.
- the mast cell degranulation releases histamine, bradykinin, and slow-reacting substance of anaphylaxis (SRS-A) which includes the leukotrienes C, D and E, prostaglandins including PGF 2 , PGF 2 ⁇ , and PGD 2 , and thromboxane A 2 .
- SRS-A anaphylaxis
- the histamine then attaches to receptor sites in the larger bronchi, causing irritation, inflammation, and edema.
- the SRS-A attaches to receptor sites in the smaller bronchi, causing edema and attracting prostaglandins, which enhance the effects of histamine in the lungs.
- Histamine in combination with prostaglandins, also stimulates excessive mucous secretion, narrowing the bronchial lumen further.
- the narrowed bronchial lumen still expands slightly, allowing air to reach the alveoli.
- the increased thoracic pressure closes the bronchial lumen completely. Therefore, air can enter the lungs, but may not exit during an asthma attack.
- the ventilation in the alveoli is then inhibited by mucous collecting in the lung bases.
- blood is shunted to other alveoli. Hypoxia, and in extreme cases, respiratory acidosis may result without medical intervention.
- the early phase includes the immediate inflammatory response including the reactions caused by the release of cellular mediators from mast cells (i.e., histamine).
- Late phase reactions develop over a period of hours and are characterized histologically by an early influx of polymorphonuclear leukocytes and fibrin deposition, later followed by infiltration of eosinophils.
- Lukacs et al. Li.cs at el, Am. J. Physiol Lung Cell Mol Physiol. 2001
- anti-C5a antibodies were administered intratracheally togeher with anti-BSA antibody during the induction of immune complex mediated lung inflammation.
- the Lukacs study uses a model of acute immune complex mediated tissue lung inflammation similar to reverse passive Arthus reaction in skin, with a brief AHR to intravenous challenges of methacholine. Animals did not develop chronic airway inflammation featured by eosinophilia; nor did they experience previous severe asthmatic attack after exposed to allergens as demonstrated in the current invention.
- the present disclosure relates to a treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components or blocks the engagement of complement component receptors, such as, for example, C5a receptors.
- the treatment therapy includes the administration of a compound that inhibits the production and/or activity of at least one complement component.
- Suitable compounds include, for example, antibodies which bind to or otherwise block the generation and/or activity of one or more complement components, such as, for example, an antibody specific to complement component C5.
- the complement-inhibiting compound can be administered prophylactically in known asthmatic individuals (such as those having established airway inflammation or a subject that has experienced previous asthmatic symptoms) to prevent, or help prevent asthma attacks.
- This prophylactic therapy can be administered via intravenous, aerosol, subcutaneous or intramuscular routes.
- the complement-inhibiting compound can be administered as a therapeutic regimen to an individual experiencing an asthma attack.
- the regimen can be administered via intravenous, aerosol, subcutaneous or intramuscular routes.
- a combination therapy may also be used that includes a complement- inhibiting compound in combination with a regimen of known asthma therapy, such as, for example, steroids, anti-lgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, ⁇ 2 receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, b2 adreno receptor agonists, PDE inhibitors, IL 5 antagonists, CD23 antagonists, IL 13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.
- a complement- inhibiting compound in combination with a regimen of known asthma therapy, such as, for example, steroids, anti-lgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, ⁇ 2 receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, b2 adreno receptor agonists, PDE inhibitors, IL 5 antagonists, CD23 antagonists, IL 13 antagonists,
- Suitable compounds of each class listed above as well as other asthma treatments are listed in Asthma Therapeutic: New Treatment Options and Emerging Drug Discovery Tasrgerts, Barnes, April 2003, Lead Discovery, http://www.leaddiscovery.co.uk/target-discovery/abstracts/dossier-asthma.html
- Asthma Therapeutic New Treatment Options and Emerging Drug Discovery Tasrgerts, Barnes, April 2003, Lead Discovery, http://www.leaddiscovery.co.uk/target-discovery/abstracts/dossier-asthma.html
- the methods include the step of administering to a subject having or susceptible to asthma a compound that reduces the release or production of inflammatory mediators (such as, for example, matrix metalloprotease 9 (mmp9 - also known as the 92-kDa type IV collagenase/gelatinase or gelatinase B), TGF ⁇ , eosinophil granules, and the like) in the airways of the subject.
- inflammatory mediators such as, for example, matrix metalloprotease 9 (mmp9 - also known as the 92-kDa type IV collagenase/gelatinase or gelatinase B), TGF ⁇ , eosinophil granules, and the like
- the compound can act at the cellular level to reduce the production or release of the inflammatory mediator, can interact with the inflammatory mediator in a manner that interfaces with its activity, (such as, for example by preventing the conversion of pro-mmp-9 to the 83 kDa active form or can interact with an active form) of the inflammatory mediator to prevent the inflammatory effects associated therewith.
- Figure 2a shows the schedule and nature of antigen challenges and prophylactic treatment of normal BALB/c Mice.
- Figure 2b shows a schedule of antigen challenge and prophylactic treatment in normal BALB/c Mice.
- Figure 3 graphically summarizes the effects of the treatments shown in
- Figure 4a shows the schedule and nature of antigen challenges and IV or aerosol treatment of normal BALB/c Mice during an asthma attack.
- Figure 4b depicts the protocol and results of induction of asthmatic attack in BALB/c Mice.
- FIGs 5a and 5b graphically summarize the effects of the aerosol treatments shown in Figure 4a.
- Figures 6a and 6b graphically summarize the effects of the intravenous treatments shown in Figure 4a.
- Figure 7 graphically depicts the systemic effects of various treatments on C5 activity for treatments shown in Figure 4a.
- Figure 8 graphically shows the effect of various intravenous treatments on the total WBC count in BAL.
- Figures 9 and 10 show that eosinophils were found to be the predominant inflammatory cells in BAL.
- FIG. 11 graphically shows the effect of various intravenous treatments on histamine and in BAL.
- FIG. 12 graphically shows the effect of various intravenous treatments on MMP-9 levels in BAL
- FIG 13 graphically shows the effect of various intravenous treatments on TGF ⁇ levels in BAL.
- Figure 14 shows the schedule and nature of antigen challenges and cannulation and aerosol treatment of normal BALB/c Mice during an asthma attack.
- Figure 15 shows lung resistance in asthmatic mice treated during an asthma attack with anti-C5, ⁇ 2 receptor agonist or a combination thereof.
- the present disclosure is directed to a method of treating asthma in mammals.
- the methods of treating asthma described herein involve using compounds which bind to or otherwise block the generation and/or activity of one or more complement components.
- the inhibition or blocking of the generation of complement components inhibits multiple factors involved in the broncho-constrictive responses in asthma.
- a specific class of such compounds which are particularly useful are antibodies specific to a human complement component, especially anti-C5 antibodies.
- the complement system acts in conjunction with other immunological systems of the body to defend against intrusion of cellular and viral pathogens.
- complement proteins There are at least 25 complement proteins, which are found as a complex collection of plasma proteins and membrane cofactors.
- the plasma proteins make up about 10% of the globulins in vertebrate serum.
- Complement components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events.
- the resulting complement cascade leads to the production of products with opsonic, immunoregulatory, and lytic functions.
- a concise summary of the biologic activities associated with complement activation is provided, for example, in The Merck Manual, 16 th Edition.
- the complement cascade progresses via the classical pathway or the alternative pathway. These pathways share many components, and while they differ in their initial steps, they converge and share the same "terminal complement” components (C5 through C9) responsible for the activation and destruction of target cells.
- the classical complement pathway is typically initiated by antibody recognition of and binding to an antigenic site on a target cell.
- the alternative pathway is usually antibody independent, and can be initiated by certain molecules on pathogen surfaces.
- the lectin pathway is typically initiated with binding of mannose-binding lectin (MBL) to high mannose substrates. These pathways converge at the point where complement component C3 is cleaved by an active protease (which is different in each pathway) to yield C3a and C3b.
- MBL mannose-binding lectin
- C3a is an anaphylatoxin.
- C3b binds to bacterial and other cells, as well as to certain viruses and immune complexes, and tags them for removal from the circulation. (C3b in this role is known as opsonin.)
- the opsonic function of C3b is generally considered to be the most important anti-infective action of the complement system. Patients with genetic lesions that block C3b function are prone to infection by a broad variety of pathogenic organisms, while patients with lesions later in the complement cascade sequence, i.e., patients with lesions that block C5 functions, are found to be more prone only to Neisseria infection, and then only somewhat more prone.
- C3b also forms a complex with other components unique to each pathway to form classical or alternative C5 convertase, which cleaves C5 into C5a and C5b.
- C3 is thus regarded as the central protein in the complement reaction sequence since it is essential to both the alternative and classical pathways.
- This property of C3b is regulated by the serum protease Factor I, which acts on C3b to produce iC3b. While still functional as opsonin, iC3b cannot form an active C5 convertase.
- C5 is a 190 kDa beta globulin found in normal serum at approximately 75 ⁇ g/ml (0.4 ⁇ M). C5 is glycosylated, with about 1.5-3 percent of its mass attributed to carbohydrate. Mature C5 is a heterodimer of a 999 amino acid 115 kDa alpha chain that is disulfide linked to a 656 amino acid 75 kDa beta chain. C5 is synthesized as a single chain precursor protein product of a single copy gene (Haviland et al. J. Immunol. 1991 , 146:362-368).
- the cDNA sequence of the transcript of this gene predicts a secreted pro-C5 precursor of 1659 amino acids along with an 18 amino acid leader sequence (see, U.S. patent 6,355,245).
- the pro-C5 precursor is cleaved after amino acid 655 and 659, to yield the beta chain as an amino terminal fragment (amino acid residues +1 to 655 of the above sequence) and the alpha chain as a carboxyl terminal fragment (amino acid residues 660 to 1658 of the above sequence), with four amino acids (amino acid residues 656-659 of the above sequence) deleted between the two.
- C5a is cleaved from the alpha chain of C5 by either alternative or classical C5 convertase as an amino terminal fragment comprising the first 74 amino acids of the alpha chain (i.e., amino acid residues 660-733 of the above sequence). Approximately 20 percent of the 11 kDa mass of C5a is attributed to carbohydrate.
- the cleavage site for convertase action is at, or immediately adjacent to, amino acid residue 733 of the above sequence. A compound that would bind at, or adjacent, to this cleavage site would have the potential to block access of the C5 convertase enzymes to the cleavage site and thereby act as a complement inhibitor.
- C5 can also be activated by means other than C5 convertase activity. Limited trypsin digestion (Minta and Man, J. Immunol. 1977, 119:1597-1602; Wetsel and Kolb, J. Immunol. 1982, 128:2209-2216) and acid treatment
- C5a and C5b-9 also have pleiotropic cell activating properties, by amplifying the release of downstream inflammatory factors, such as hydrolytic enzymes, reactive oxygen species arachidonic acid metabolites and various cytokines.
- C5b combines with C6, C7, and C8 to form the C5b-8 complex at the surface of the target cell.
- the membrane attack complex (MAC, C5b-9, terminal complement complex-TCC) is formed.
- MAC membrane attack complex
- C5b-9 terminal complement complex-TCC
- MAC pores mediate rapid osmotic lysis of the target cells.
- non-lytic concentrations of MACs can produce other effects.
- membrane insertion of small numbers of the C5b-9 complexes into endothelial cells and platelets can cause deleterious cell activation. In some cases activation may precede cell lysis.
- C3a and C5a are anaphylatoxins. These activated complement components can trigger mast cell degranulation, which releases histamine from basophiis and mast cells, and other mediators of inflammation, resulting in smooth muscle contraction, increased vascular permeability, leukocyte activation, and other inflammatory phenomena including cellular proliferation resulting in hypercellularity.
- C5a also functions as a chemotactic peptide that serves to attract pro-inflammatory granulocytes to the site of complement activation.
- C5a receptors are found on the surfaces of bronchial and alveolar epithelial cells and bronchial smooth muscles cells. C5a receptors have also been found on eosinophils, mast cells, monocytes, neutrophils, and activated lymphocytes. Thus, compounds that block engagement of receptors of complement components are useful herein.
- any compounds which bind to or otherwise block the generation and/or activity of any of the human complement components such as, for example, antibodies specific to a human complement component are useful herein.
- Some compounds include antibodies directed against complement components C-1 , C- 2, C-3, C-4, C-5, C-6, C-7, C-8, C-9, Factor D, Factor B, Factor P, MBL, MASP-1 , AND MASP-2, thus preventing the generation of the anaphylatoxic activity associated with C5a and preventing the assembly of the membrane attack complex associated with C5b.
- complement inhibitory compounds such as CR1 , LEX-CR1 , MCP, DAF, CD59, Factor H, cobra venom factor, FUT-175, y bind protein, complestatin, and K76 COOH.
- Particularly useful compounds for use herein are antibodies that reduce, directly or indirectly, the conversion of complement component C5 into complement components C5a and C5b.
- One class of useful antibodies are those having at least one antibody-antigen binding site and exhibiting specific binding to human complement component C5, wherein the specific binding is targeted to the alpha chain of human complement component C5. More particularly, a monoclonal antibody (mAb) may be used.
- Such an antibody 1) inhibits complement activation in a human body fluid; 2) inhibits the binding of purified human complement component C5 to either human complement component C3 or human complement component C4; and 3) does not specifically bind to the human complement activation product for C5a.
- Particularly useful complement inhibitors are compounds which reduce the generation of C5a and/or C5b-9 by greater than about 30%.
- Anti-C5 antibodies that have the desirable ability to block the generation of C5a have been known in the art since at least 1982 (Moongkarndi et al. Immunobiol. 1982, 162:397;
- anti-C5 antibodies are h5G1.1 , h5G1.1-scFv and functional fragments of h5G1.1.
- Methods for the preparation of h5G1.1 , h5G1.1-scFv and functional fragments of h5G1.1 are described in U.S. Patent No. 6,355,245 and "Inhibition of Complement Activity by Humanized Anti-C5 Antibody and Single Chain Fv", Thomas et al., Molecular Immunology, Vol. 33, No. 17/18, pages 1389-1401 , 1996, the disclosures of which are incorporated herein in their entirety by this reference.
- a suitable antibody inhibits the cleavage of C5, which blocks the generation of potent proinflammatory molecules C5a and C5b-9 (terminal complement complex).
- the antibody does not prevent the formation of C3b, which subserves critical immunoprotective functions of opsonization and immune complex clearance.
- the anti-human C5 antibody is preferably a monoclonal antibody, although polyclonal antibodies produced and screened by conventional techniques can also be used if desired.
- the preferred anti-C5 antibodies used to treat asthma in accordance with this disclosure bind to C5 or fragments thereof, e.g., C5a or C5b.
- the anti-C5 antibodies are immunoreactive against epitopes on the alpha chain of purified human complement component C5 and are capable of blocking the conversion of C5 into C5a and C5b by C5 convertase. This capability can be measured using the techniques described in Wurzner, et al., Complement Inflamm 8:328-340, 1991.
- the anti-C5 antibodies are not immunoreactive against epitopes on the beta chain, but rather are immunoreactive against epitopes within the alpha chain of purified human complement component C5.
- the antibodies are also capable of blocking the conversion of C5 into C5a and C5b by C5 convertase.
- the most preferred antibodies bind to an amino-terminal region, however, they do not bind to free C5a.
- Hybridomas producing monoclonal antibodies reactive with complement component C5 can be obtained according to the teachings of Sims, et al., U.S. Pat. No. 5,135,916.
- Antibodies are prepared using purified components of the complement membrane attack complex as immunogens according to known methods.
- complement component C5 or C5b is preferably used as the immunogen.
- the immunogen is the alpha chain of C5.
- a method of reducing inflammation in the lungs of asthma patients includes the step of administering to a subject having or susceptible to asthma a compound that reduces the production or release of inflammatory mediators in the airway of the subject.
- inflammatory mediators include TGF ⁇ , eosinophil granule proteins, and matrix metalloprotease 9 (mmp9 - also known as the 92-kDa type IV collagenase/gelatinase or gelatinase B).
- the compounds can reduce inflammation by any variety of mechanisms.
- the compound can act at the cellular level to reduce the production or release of pro- mmp-9, can interact with pro-mmp-9 in a manner that prevents conversion of pro- mmp-9 to the 83 kDa active form or can interact with the active form of mmp9 to prevent the inflammatory effects associated with the enzyme (such as, for example, the generation of TGF-beta).
- Suitable compounds include, but are not limited to, the compounds described above which bind to or otherwise block the generation and/or release an/or activity of one or more complement components or block engagement of the receptors of complement components.
- MMP-9 activity can be detected in accordance with a variety of art- recognized procedures. For example, quantitative zymographic methods provide a relatively refined assessment of the activity of this enzyme. This method allows for the detection of MMP-9 activity based upon the ability of the enzyme to hydrolyze denatured collagen, i.e., gelatin, which is a natural substrate for MMP- 9. The gelatin is incorporated into a gel such as polyacrylamide. See Hibbs et al., J. Biol. Chem. 260:2493-2500 (1985) and Moll et al., Cancer Res. 50:6162-70 (1990). The assay may be standardized using a purified MMP-9 preparation that is analyzed in parallel with the test sample.
- Purified MMP-9 can be prepared by methods known in the art. See, for example, Okada et al., supra., and Morodomi et al., Biochem J. 285:603:11 (1992).
- the extent of hydrolysis of the gelatin is directly related to the activity of MMP-9 in the sample, and the active MMP-9 forms can be identified by their characteristic molecular weights.
- the proMMP-9 species can be detected because of the catalytic activation that occurs during electrophoresis and subsequent incubation.
- the MMP-9 forms present prior to the onset of labor are incapable of undergoing this kind of activation, i.e., they are latent.
- MMP-9 activity can also be detected using standard immunological techniques, e.g., ELISA, immunofluorescence assays, or radioimmunoassays.
- MMP-9 activity is detected using ELISA, which entails the use of antibodies specific to MMP-9. See David et al, U.S. Pat. No. 4,376,110 (and references cited therein).
- Monoclonal antibodies specific to MMP-9 have been prepared using partially purified enzyme preparations. See, e.g., Moll et al., supra; Ramos-DeSimone et al., HYBRIDOMA 12(4):349-63 (1993) and Goldberg et al.
- Polyclonal antibodies specific to MMP-9 can also be prepared in accordance with standard procedures.
- polyclonal antibodies are prepared using non-conserved peptides conjugated to a macromolecular carrier.
- the choice of a specific non-conserved peptide such as the metal-binding domain, among the members of the MMPs is considered within a level of ordinary skill in the art. See Woessner, and Goldberg et al., supra. Enzymic assays that can detect MMP-9 in picogram or nanogram amounts are also disclosed in Manicourt et al., Anal. Biochem. 215(2):171-9 (1993).
- MMP-9 activity can further be detected in a sample by western blot analysis, which requires electrophoretic separation of the test material in a gel, followed by transfer of the separated proteins to a nitrocellulose membrane and detection of the MMP-9 antigens with a specific antibody and reagent that reacts with the antigen-fixed antibody.
- western blot analysis requires electrophoretic separation of the test material in a gel, followed by transfer of the separated proteins to a nitrocellulose membrane and detection of the MMP-9 antigens with a specific antibody and reagent that reacts with the antigen-fixed antibody.
- the compound that inhibits the production and/or activity of at least one complement component can be administered in a variety of unit dosage forms.
- the dose will vary according to the particular compound employed. For example, different antibodies may have different masses and/or affinities, and thus require different dosage levels.
- Antibodies prepared as Fab' fragments will also require differing dosages than the equivalent intact immunoglobulins, as they are of considerably smaller mass than intact immunoglobulins, and thus require lower dosages to reach the same molar levels in the patient's blood.
- the dose will also vary depending on the manner of administration, the particular symptoms of the patient being treated, the overall health, condition, size, and age of the patient, and the judgment of the prescribing physician.
- Administration of the compound that inhibits the production and/or activity of at least one complement component will generally be in an aerosol form with a suitable pharmaceutical carrier, via intravenous infusion by injection, or subcutaneous injection. Other routes of administration may be used if desired. Aerosol administration is preferred since it avoids the systemic effects of the complement-inhibiting compound, while providing the desired asthma-treating effects to be achieved in accordance with this disclosure.
- Formulations suitable for injection are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985). Such formulations must be sterile and non-pyrogenic, and generally will include a pharmaceutically effective carrier, such as saline, buffered (e.g., phosphate buffered) saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions, and the like.
- the formulations may contain pharmaceutically acceptable auxiliary substances as required, such as, tonicity adjusting agents, wetting agents, bactericidal agents, preservatives, stabilizers, and the like.
- Ovalbumin antigen and Alum, according to the dosages and schedule shown in Figure 4b. These exposures solicited the standard asthmatic response during an attack.
- the exposed mice showed both early phase and late phase reactions. As seen in Figure 1 , the early phase reaction was specific airway resistance within 15 minutes after exposure. A more severe late phase reaction of specific airway resistance occurred approximately 5 hours after exposure. Specific airway resistance was measured by means of double chamber plethysmograph fitted with pneumotachographs, which is commercially available from the Buxo Corporation.
- To demonstrate the prophylactic benefits of a complement component inhibiting compound groups of mice were given one of three different treatments in accordance with the schedule of dosages shown in Figures 2a and 2b.
- the positive control group was treated with a control antibody (hybridoma 135.8) at a dose of 40 mg/kg.
- a second group of mice was treated with the anti-C5 antibody, BB5.1 , at a dose of 40mg/kg.
- a third group of mice was treated with Dexamethasone ("DEX").
- a negative control group was initially exposed to PBS (phosphate buffer saline) and Alum, and was later given PBS as shown in the schedule of Figure 2a. This control group provided a baseline air resistance measurement.
- the BB5.1 antibody is made according to known methods. (See, Frei, Y.,
- EXAMPLE 2 The Use Of Anti-C5 Antibodies Via Intravenous Administration As A Therapeutic Method To Treat Asthma
- mice were given one of three different treatments in accordance with the schedule of dosages shown in Figure 4a.
- a positive control group was challenged with OVA and treated with a control antibody (135.8 hybridoma) administered intravenously, 15 minutes after provoking the initial asthmatic attack.
- a second group of mice were similarly challenged and intravenously treated with BB5.1 , the anti-C5 antibody, 15 minutes after provoking the initial asthmatic attack.
- a third group of mice were similarly challenged and intravenously treated with DEX, 15 minutes after provoking the initial asthmatic attack.
- Sham operated mice provided baseline air resistance measurement which was provided by administering phosphorate buffer solution (PBS) and alum to a group of mice, and administering aerosol doses of PBS according to the schedule shown on Fig. 4a.
- PBS phosphorate buffer solution
- mice treated therapeutically with anti-C5 intravenously showed very little specific airway constriction and these mice responded to the treatments as well as the group treated with the steroid, DEX.
- the positive control group that was treated with a control antibody showed significantly increased specific airway resistance, as shown in Figure 6a.
- the anti-C5 antibody had inhibited the inflammatory response of the complement components, and allowed greater air passage during the asthma attacks in the mice.
- mice were given one of three different treatments in accordance with the schedule of dosages shown in Figure 4a.
- a positive control group was challenged with OVA and treated with a control antibody (135.8 hybridoma) administered by aerosol, 15 minutes after provoking the initial asthmatic attack.
- a second group of mice were similarly challenged and treated via aerosol administration of BB5.1 , an anti-C5 antibody, 15 minutes after provoking the initial asthmatic attack.
- a third group of mice were similarly challenged and treated by aerosol with DEX, 15 minutes after provoking the initial asthmatic attack.
- a baseline air resistance measurement was provided by administering phosphorate buffer solution (PBS) and alum to a group of mice, and administering aerosol doses of PBS according to the schedule shown on Fig. 4a. It was found that therapeutic aerosol treatments of mice with anti-C5 antibody, BB5.1 during asthma attacks significantly lowered the specific airway resistance and these mice responded as well as, and more quickly than, the steroid treated mice. The results of the aerosol treatments are shown in Figures 5a and 5b. The positive control group that was treated with a control antibody experienced specific airway resistance many times greater than the mice treated with anti-C5 antibody, as shown in Figure 5b.
- PBS phosphorate buffer solution
- Anti-C5 antibody, BB5.1 was also administered to the test animals through nebulization, which was found to be an effective method of administration. Results of serum tests after nebulization indicate that the BB5.1 was binding with the C5 site and, therefore, remained intact during delivery through nebulization.
- mice were given one of three different treatments in accordance with the schedule of dosages shown in Figure 4a.
- a positive control group was challenged with OVA and treated with a control antibody (135.8 hybridoma) administered intravenously, 15 minutes after provoking the initial asthmatic attack.
- a second group of mice were similarly challenged and intravenously treated with BB5.1 , the anti-C5 antibody, 15 minutes after provoking the initial asthmatic attack.
- a third group of mice were similarly challenged and intravenously treated with DEX, 15 minutes after provoking the initial asthmatic attack.
- mice provided baseline air resistance measurement which was provided by administering phosphorate buffer solution (PBS) and alum to a group of mice, and administering aerosol doses of PBS according to the schedule shown on Fig. 4a.
- PBS phosphorate buffer solution
- alum alum
- aerosol doses of PBS according to the schedule shown on Fig. 4a.
- the mice were euthanized and the lungs were lavaged using conventional techniques.
- 1 cc of PBI saline was introduced into the lungs and recovered. This process was repeated three times. The fluid was recovered and centrifuged. The cells contained in the resulting pellet were inspected. The supernatant was tested for the presence of histamine, IL-5, IL-4, IL-13, Eosinophils granule proteins, TGF ⁇ and/or mmp-9.
- Figure 11 shows that the anti-C5 antibody had little effect on histamine level, a result similar to that obtained with the steroid DEX.
- the anti-C5 antibody significantly reduced the level of mmp-9 detected in BAL as shown in Figure 12, compared to treatment with Steroid.
- both anti-C5 antibody and DEX resulted in a lower detectable amount of TGF- ⁇ (see Fig. 13), only the anti-C5 antibody did so through a mechanism that involved a reduction in production or release of mmp-9.
- EXAMPLE 5 The Use Of Anti-C5 Antibodies As Bronchial Dilator
- a C5 complement component inhibitor alone or in combination with a ⁇ 2 adreno receptor agonist
- groups of mice were challenged with antigen and given one of four different treatments in accordance with the schedule of dosages shown in Figures 14 and 15.
- a positive control group was challenged with OVA, cannulated and treated with a control antibody (mouse lgG1) administered via aerosol after provoking a second asthmatic attack.
- a second group of mice were similarly challenged and treated with BB5.1 , an anti-C5 antibody after provoking a second asthmatic attack.
- mice were similarly challenged and treated with salbutamol (a ⁇ 2 adreno receptor agonist commercially available from Sigma) after provoking a second asthmatic attack.
- a fourth group of mice were similarly challenged and treated with a combination of anti-C5 antibody and salbutamol after provoking a second asthmatic attack. Sham operated mice provided baseline air resistance measurement which was provided by administering phosphorate buffer solution (PBS) and alum to a group of mice, and administering aerosol doses of PBS according to the schedule shown on Figs. 14 and 15.
- PBS phosphorate buffer solution
- Airway responsiveness was then assessed as a change in airway function by an invasive method wherein changes in lung resistance were measured by using Buxco Biosystem software and whole body plethysmograph.
- Mice were anesthetized with Avertin (160mg/kg) by i.p. injection and ventilated by a Harvard Apparatus Inspira ventilator. After tracheal cannula, pancuronium (0.3mg/kg) was injected intraperitoneally to induce paralysis and inhibit spontaneous breathing. The mice are kept breathing by a ventilator, which is set at a tidal volume and respiratory rate by program of body weight. The measurements of RL to specific antigen were performed at 5 hours after 5% OVA provocation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003270330A AU2003270330B2 (en) | 2002-09-06 | 2003-09-05 | Method of treatment of asthma using antibodies to complement component C5 |
EP03752016.0A EP1545611B1 (en) | 2002-09-06 | 2003-09-05 | Method of treatment of asthma using antibodies to complement component c5 |
NZ538384A NZ538384A (en) | 2002-09-06 | 2003-09-05 | Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors |
CA2496834A CA2496834C (en) | 2002-09-06 | 2003-09-05 | Method of treatment of asthma using antibodies to complement component c5 |
JP2004534616A JP4601426B2 (en) | 2002-09-06 | 2003-09-05 | Method for the treatment of asthma using antibodies against complement component C5 |
ES03752016.0T ES2614274T3 (en) | 2002-09-06 | 2003-09-05 | Asthma treatment procedure using antibodies against complement component C5 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40857102P | 2002-09-06 | 2002-09-06 | |
US60/408,571 | 2002-09-06 | ||
US46918903P | 2003-05-09 | 2003-05-09 | |
US60/469,189 | 2003-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004022096A1 true WO2004022096A1 (en) | 2004-03-18 |
Family
ID=31981600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/027808 WO2004022096A1 (en) | 2002-09-06 | 2003-09-05 | Method of treatment of asthma using antibodies to complement component c5 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040115194A1 (en) |
EP (1) | EP1545611B1 (en) |
JP (3) | JP4601426B2 (en) |
AU (2) | AU2003270330B2 (en) |
CA (1) | CA2496834C (en) |
ES (1) | ES2614274T3 (en) |
NZ (1) | NZ538384A (en) |
WO (1) | WO2004022096A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122257A2 (en) * | 2005-05-11 | 2006-11-16 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
WO2007049017A2 (en) * | 2005-10-24 | 2007-05-03 | Domantis Limited | Agents that bind a target in pulmonary tissue for treating respiratory diseases |
WO2008090366A1 (en) * | 2007-01-25 | 2008-07-31 | Mucokinetica Ltd. | Treatment for respiratory disease |
US7585500B2 (en) | 2004-11-17 | 2009-09-08 | Amgen Inc. | Fully human monoclonal antibodies to IL-13 |
CN101839910A (en) * | 2010-05-07 | 2010-09-22 | 刘东旭 | Specific antibody of spontaneous immunological diseases and related diagnostic reagent kit of spontaneous immunological diseases |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2305639A2 (en) * | 2005-04-14 | 2011-04-06 | Novartis AG | Organic compounds |
US7964705B2 (en) | 2007-03-14 | 2011-06-21 | Taligen Therapeutics, Inc. | Humaneered anti-factor B antibody |
EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
US7999082B2 (en) | 2004-02-10 | 2011-08-16 | National Jewish Medical And Research Center | Anti-factor B antibodies |
EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
US8377443B2 (en) | 2010-08-27 | 2013-02-19 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
US8398979B2 (en) | 2007-06-06 | 2013-03-19 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
WO2013130078A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
US8551790B2 (en) | 1997-04-03 | 2013-10-08 | Helion Biotech Aps | MASP 2, a complement-fixing enzyme, and uses for it |
US8580735B2 (en) | 2007-02-05 | 2013-11-12 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
US8652477B2 (en) | 2009-10-16 | 2014-02-18 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8911733B2 (en) | 2005-05-26 | 2014-12-16 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US9096676B2 (en) | 2003-05-12 | 2015-08-04 | Helion Biotech Aps | Antibodies to MASP-2 |
US9352035B2 (en) | 2002-09-06 | 2016-05-31 | Alexion Pharmaceuticals, Inc. | High concentration antibody formulations |
US9447176B2 (en) | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
US9494601B2 (en) | 2013-08-07 | 2016-11-15 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (AHUS) biomarker proteins |
US9562090B2 (en) | 2007-12-13 | 2017-02-07 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US9732156B2 (en) | 2012-02-29 | 2017-08-15 | Gilead Biologics, Inc. | Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9 |
US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
US11365265B2 (en) | 2017-12-13 | 2022-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
WO2006017752A2 (en) * | 2004-08-05 | 2006-02-16 | Ivax Corporation | Sulfated oligosaccharides |
JP2010502687A (en) * | 2006-09-08 | 2010-01-28 | ヴァーレイ・リミテッド | Respiratory disease treatment methods |
GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
CN110818798A (en) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | Anti-complement C1s antibodies and uses thereof |
EP2914291B1 (en) | 2012-11-02 | 2022-02-23 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
HRP20230093T1 (en) | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanized anti-c1s antibodies and methods of use thereof |
IL256424B1 (en) * | 2015-06-26 | 2024-05-01 | Bioverativ Usa Inc | Methods of treating autoimmune and alloimmune disorders |
JOP20170154B1 (en) * | 2016-08-01 | 2023-03-28 | Omeros Corp | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
KR102204097B1 (en) * | 2019-01-31 | 2021-01-18 | 동신대학교 산학협력단 | Composition for preventing or treating asthmatic disease comprising fatty acids |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
EP0411306A1 (en) | 1989-07-27 | 1991-02-06 | Götze, Otto Prof. Dr. med. | Procedure for the detection and/or quantitative determination of complement peptide C5a and/or C5a-des-arg |
US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
EP0649468B1 (en) * | 1992-06-24 | 2000-03-15 | AdProTech plc | Soluble cr1 derivatives |
US6316502B1 (en) * | 1998-06-23 | 2001-11-13 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor |
US6355245B1 (en) | 1994-05-02 | 2002-03-12 | Alexion Pharmaceuticals, Inc. | C5-specific antibodies for the treatment of inflammatory diseases |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228795A (en) * | 1977-03-08 | 1980-10-21 | Babington Robert S | Apparatus for producing finely divided liquid spray |
US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
US5614370A (en) * | 1994-03-18 | 1997-03-25 | Merck & Co., Inc. | Assay to identify human C5a antagonists and agonists |
US20010036650A1 (en) * | 1994-08-16 | 2001-11-01 | Human Genome Sciences, Inc. | C5a receptor |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
JP2001503406A (en) * | 1996-10-28 | 2001-03-13 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | Pharmaceutical composition |
US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
EP1100494A1 (en) * | 1998-07-30 | 2001-05-23 | Novopharm Biotech, Inc. | Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin |
US6280994B1 (en) * | 1998-11-25 | 2001-08-28 | Zymogenetics, Inc. | Zace 1: a human metalloenzyme |
CZ20022413A3 (en) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes |
ATE435873T1 (en) * | 2000-03-23 | 2009-07-15 | Genentech Inc | ANTI-C2/C2A INHIBITORS FOR COMPLEMENT ACTIVATION |
AU2001259063A1 (en) * | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
AU2001282857A1 (en) * | 2000-06-21 | 2002-01-02 | Zymogenetics Inc. | Peptide and polypeptide inhibitors of complement c1s |
AU2002256971B2 (en) * | 2000-12-28 | 2008-04-03 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
WO2003084524A1 (en) * | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
JP4728948B2 (en) * | 2003-02-10 | 2011-07-20 | エラン ファーマシューティカルズ,インコーポレイテッド | Immunoglobulin preparation and method for its preparation |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
KR20080098504A (en) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | Protein formulations |
CN101600457B (en) * | 2007-01-09 | 2014-01-08 | 惠氏公司 | Anti-il-13 antibody formulations and uses thereof |
-
2003
- 2003-09-05 EP EP03752016.0A patent/EP1545611B1/en not_active Expired - Lifetime
- 2003-09-05 WO PCT/US2003/027808 patent/WO2004022096A1/en active Application Filing
- 2003-09-05 US US10/655,861 patent/US20040115194A1/en not_active Abandoned
- 2003-09-05 AU AU2003270330A patent/AU2003270330B2/en not_active Ceased
- 2003-09-05 NZ NZ538384A patent/NZ538384A/en not_active IP Right Cessation
- 2003-09-05 JP JP2004534616A patent/JP4601426B2/en not_active Expired - Fee Related
- 2003-09-05 ES ES03752016.0T patent/ES2614274T3/en not_active Expired - Lifetime
- 2003-09-05 CA CA2496834A patent/CA2496834C/en not_active Expired - Fee Related
-
2009
- 2009-10-08 AU AU2009222630A patent/AU2009222630A1/en not_active Ceased
-
2010
- 2010-02-10 JP JP2010028219A patent/JP5137983B2/en not_active Expired - Fee Related
- 2010-07-09 JP JP2010157203A patent/JP2010215674A/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
EP0411306A1 (en) | 1989-07-27 | 1991-02-06 | Götze, Otto Prof. Dr. med. | Procedure for the detection and/or quantitative determination of complement peptide C5a and/or C5a-des-arg |
EP0649468B1 (en) * | 1992-06-24 | 2000-03-15 | AdProTech plc | Soluble cr1 derivatives |
US6355245B1 (en) | 1994-05-02 | 2002-03-12 | Alexion Pharmaceuticals, Inc. | C5-specific antibodies for the treatment of inflammatory diseases |
US6316502B1 (en) * | 1998-06-23 | 2001-11-13 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor |
Non-Patent Citations (17)
Title |
---|
ABE ET AL., J IMMUNOL., vol. 167, no. 8, 15 October 2001 (2001-10-15), pages 4651 - 60 |
AMES ET AL., J. LMMUNOL., vol. 152, 1994, pages 4572 - 4581 |
BARNES: "Asthma Therapeutic: New Treatment Options and Emerging Drug Discovery Tasrgerts", LEAD DISCOVERY, April 2003 (2003-04-01), Retrieved from the Internet <URL:http://www.leaddiscovery.co.uk/target-discovery/abstracts/dossier-asthma.html> |
GICLAS ET AL., J. EMMUNOL. METH., vol. 105, 1987, pages 201 - 209 |
JOHNE ET AL., J. LMMUNOL. METH., vol. 160, 1993, pages 191 - 198 |
KRUG ET AL., AM J RESPIR CRIT CARE MED., vol. 164, 15 November 2001 (2001-11-15), pages 1841 - 3 |
LUKACS, AM. J. PHYSIOL LUNG CELL MOL PHYSIOL., vol. 280, 2001, pages L512 - L518 |
MANICOURT ET AL., ANAL. BIOCHEM., vol. 215, no. 2, 1993, pages 171 - 9 |
MOLLNES, SCAND. J. IMMUNOL., vol. 28, 1988, pages 307 - 312 |
MOONGKARNDI ET AL., IMMUNOBIOT., vol. 162, 1982, pages 397 |
MOONGKARNDI ET AL., LMMUNOBIOL., vol. 165, 1983, pages 323 |
RAMOS-DESIMONE ET AL., HYBRIDOMA, vol. 12, no. 4, 1993, pages 349 - 63 |
See also references of EP1545611A4 |
THOMAS ET AL., MOL IMMUNOL., vol. 33, no. 17-18, December 1996 (1996-12-01), pages 1389 - 401 |
THOMAS ET AL.: "Inhibition of Complement Activity by Humanized Anti-C5 Antibody and Single Chain Fv", MOLECULAR IMMUNOLOGY, vol. 33, no. 17/18, 1996, pages 1389 - 1401 |
TOWBIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 76, no. 9, 1979, pages 4350 - 4354 |
WURZNER, COMPLEMENT INFLAMM, vol. 8, 1991, pages 328 - 340 |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551790B2 (en) | 1997-04-03 | 2013-10-08 | Helion Biotech Aps | MASP 2, a complement-fixing enzyme, and uses for it |
US9441262B2 (en) | 1997-04-03 | 2016-09-13 | Helion Biotech Aps | MASP-2, a complement fixing enzyme, and uses for it |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US9352035B2 (en) | 2002-09-06 | 2016-05-31 | Alexion Pharmaceuticals, Inc. | High concentration antibody formulations |
US10189909B2 (en) | 2003-05-12 | 2019-01-29 | Helion Biotech Aps | Antibodies to MASP-2 |
US11008404B2 (en) | 2003-05-12 | 2021-05-18 | Helion Biotech Aps | Antibodies to MASP-2 |
US11008405B2 (en) | 2003-05-12 | 2021-05-18 | Helion Biotech Aps | Antibodies to MASP-2 |
US11225526B2 (en) | 2003-05-12 | 2022-01-18 | Helion Biotech Aps | Antibodies to MASP-2 |
US9096676B2 (en) | 2003-05-12 | 2015-08-04 | Helion Biotech Aps | Antibodies to MASP-2 |
US7999082B2 (en) | 2004-02-10 | 2011-08-16 | National Jewish Medical And Research Center | Anti-factor B antibodies |
EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
US8703140B2 (en) | 2004-02-10 | 2014-04-22 | Musc Foundation For Research Development | Inhibition of factor B, the alternative complement pathway and methods related thereto |
US8652475B2 (en) | 2004-02-10 | 2014-02-18 | Musc Foundation For Research Development | Inhibition of factor B, the alternative complement pathway and methods related thereto |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US11884742B2 (en) | 2004-06-10 | 2024-01-30 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7585500B2 (en) | 2004-11-17 | 2009-09-08 | Amgen Inc. | Fully human monoclonal antibodies to IL-13 |
EP2305639A2 (en) * | 2005-04-14 | 2011-04-06 | Novartis AG | Organic compounds |
WO2006122257A2 (en) * | 2005-05-11 | 2006-11-16 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
AU2006243994B2 (en) * | 2005-05-11 | 2012-03-01 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US10927166B2 (en) | 2005-05-11 | 2021-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising an anti-C5 antibody |
JP2008540563A (en) * | 2005-05-11 | 2008-11-20 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Nebulization of monoclonal antibodies to treat lung disease |
US10479828B2 (en) | 2005-05-11 | 2019-11-19 | Alexion Pharmaceuticals, Inc. | Compositions comprising an anti-C5 antibody |
JP2012233013A (en) * | 2005-05-11 | 2012-11-29 | Alexion Pharmaceuticals Inc | Nebulization of monoclonal antibody for treating pulmonary disease |
US10125191B2 (en) | 2005-05-11 | 2018-11-13 | Alexion Pharmaceutiacls, Inc. | Compositions comprising an anti-C5 antibody |
WO2006122257A3 (en) * | 2005-05-11 | 2007-02-01 | Alexion Pharma Inc | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US8911733B2 (en) | 2005-05-26 | 2014-12-16 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
US9629909B2 (en) | 2005-10-24 | 2017-04-25 | Domantis Limited | Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue |
US8129503B2 (en) | 2005-10-24 | 2012-03-06 | Domantis Limited | Agents that bind a target in pulmonary tissue for targeting respiratory diseases |
WO2007049017A3 (en) * | 2005-10-24 | 2008-01-31 | Domantis Ltd | Agents that bind a target in pulmonary tissue for treating respiratory diseases |
WO2007049017A2 (en) * | 2005-10-24 | 2007-05-03 | Domantis Limited | Agents that bind a target in pulmonary tissue for treating respiratory diseases |
EA014106B1 (en) * | 2005-10-24 | 2010-10-29 | Домантис Лимитед | Agents that bind a target in pulmonary tissue for treating respiratory diseases |
US8497244B2 (en) | 2005-10-24 | 2013-07-30 | Domantis Limited | Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue |
JP2009512672A (en) * | 2005-10-24 | 2009-03-26 | ドマンティス リミテッド | Drugs that bind to targets in lung tissue to treat respiratory diseases |
WO2008090366A1 (en) * | 2007-01-25 | 2008-07-31 | Mucokinetica Ltd. | Treatment for respiratory disease |
US8580735B2 (en) | 2007-02-05 | 2013-11-12 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
US7964705B2 (en) | 2007-03-14 | 2011-06-21 | Taligen Therapeutics, Inc. | Humaneered anti-factor B antibody |
US9096677B2 (en) | 2007-03-14 | 2015-08-04 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
US10072089B2 (en) | 2007-06-06 | 2018-09-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US8398979B2 (en) | 2007-06-06 | 2013-03-19 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US9562090B2 (en) | 2007-12-13 | 2017-02-07 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US9771418B2 (en) | 2008-11-10 | 2017-09-26 | Alexion Pharmaceuticals, Inc. | Methods for treating complement-associated disorders |
US9447176B2 (en) | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
US11807678B2 (en) | 2008-11-10 | 2023-11-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US8652477B2 (en) | 2009-10-16 | 2014-02-18 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
CN101839910A (en) * | 2010-05-07 | 2010-09-22 | 刘东旭 | Specific antibody of spontaneous immunological diseases and related diagnostic reagent kit of spontaneous immunological diseases |
US8501916B2 (en) | 2010-08-27 | 2013-08-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
US8377443B2 (en) | 2010-08-27 | 2013-02-19 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
US9120863B2 (en) | 2010-08-27 | 2015-09-01 | Gilead Sciences, Inc. | Nucleic acids encoding antibodies to matrix metalloproteinase 9 |
US9260532B2 (en) | 2010-08-27 | 2016-02-16 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
WO2012085090A1 (en) | 2010-12-21 | 2012-06-28 | Affiris Ag | Vaccines based on peptides of the complement protein c5a |
US9925262B2 (en) | 2011-03-08 | 2018-03-27 | Alexion Pharmaceuticals, Inc. | Kits comprising formulations of anti-C5 antibodies |
US9409980B1 (en) | 2011-03-08 | 2016-08-09 | Alexion Pharmaceuticals, Inc. | Methods for treating patients with complement-associated disorders with high concentration formulations of anti-C5 antibodies |
US9556263B2 (en) | 2011-03-08 | 2017-01-31 | Alexion Pharmaceuticals, Inc. | Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodies |
US10800857B2 (en) | 2012-02-29 | 2020-10-13 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
US9732156B2 (en) | 2012-02-29 | 2017-08-15 | Gilead Biologics, Inc. | Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9 |
US11634505B2 (en) | 2012-02-29 | 2023-04-25 | Gilead Sciences, Inc. | Antibodies to matrix metalloproteinase 9 |
WO2013130078A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
US9658236B2 (en) | 2013-08-07 | 2017-05-23 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
US9494601B2 (en) | 2013-08-07 | 2016-11-15 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (AHUS) biomarker proteins |
US12025621B2 (en) | 2013-08-07 | 2024-07-02 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (AHUS) biomarker proteins |
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
US11479602B2 (en) | 2016-06-14 | 2022-10-25 | Regeneren Pharmaceuticals, Inc. | Methods of treating C5-associated diseases comprising administering anti-C5 antibodies |
US11492392B2 (en) | 2016-06-14 | 2022-11-08 | Regeneran Pharmaceuticals, Inc. | Polynucleotides encoding anti-C5 antibodies |
US11365265B2 (en) | 2017-12-13 | 2022-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5137983B2 (en) | 2013-02-06 |
CA2496834C (en) | 2014-03-18 |
JP2010100662A (en) | 2010-05-06 |
AU2003270330A1 (en) | 2004-03-29 |
NZ538384A (en) | 2009-04-30 |
EP1545611A4 (en) | 2006-03-22 |
JP2006500392A (en) | 2006-01-05 |
EP1545611A1 (en) | 2005-06-29 |
JP2010215674A (en) | 2010-09-30 |
AU2003270330B2 (en) | 2009-07-30 |
US20040115194A1 (en) | 2004-06-17 |
AU2009222630A1 (en) | 2009-10-29 |
EP1545611B1 (en) | 2016-11-09 |
JP4601426B2 (en) | 2010-12-22 |
CA2496834A1 (en) | 2004-03-18 |
ES2614274T3 (en) | 2017-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1545611B1 (en) | Method of treatment of asthma using antibodies to complement component c5 | |
JP5137053B2 (en) | Anti-factor B antibody or antigen-binding fragment thereof, composition containing the same, antigen-binding polypeptide, and therapeutic agent | |
US7964705B2 (en) | Humaneered anti-factor B antibody | |
EP1713503B1 (en) | Inhibition of factor b, the alternative complement pathway and methods related thereto | |
JP2006500392A5 (en) | ||
US11504426B2 (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist | |
US20060222646A1 (en) | Anti-TNFalpha antibodies in therapy of asthma | |
JP2015028042A (en) | Method for administering anti il-5 antibody | |
JP2010539243A (en) | LIGHT inhibitors for the treatment of asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic diseases | |
US20220220211A1 (en) | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003270330 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538384 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2496834 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2003752016 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003752016 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004534616 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003752016 Country of ref document: EP |